Retrospective observational study of HER2 immunohistochemistry in borderline breast cancer patients undergoing neoadjuvant therapy, with an emphasis on Group 2 (HER2/CEP17 ratio ≥2.0, HER2 copy number <4.0 signals/cell) cases

BACKGROUND: The ASCO/CAP guidance on HER2 testing in breast cancer (BC) has recently changed. Group 2 tumours with immunohistochemistry score 2+ and HER2/CEP17 ratio ≥2.0 and HER2 copy number <4.0 signals/cell were re-classified as HER2 negative. This study aims to examine the response of Group 2...

Descripción completa

Detalles Bibliográficos
Autores principales: Rakha, Emad A., Miligy, Islam M., Quinn, Cecily M., Provenzano, Elena, Shaaban, Abeer M., Marchiò, Caterina, Toss, Michael S., Gallagy, Grace, Murray, Ciara, Walshe, Janice, Katayama, Ayaka, Eldib, Karim, Badr, Nahla, Tanchel, Bruce, Millican-Slater, Rebecca, Purdie, Colin, Purnell, Dave, Pinder, Sarah E., Ellis, Ian O., Lee, Andrew H. S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144199/
https://www.ncbi.nlm.nih.gov/pubmed/33762723
http://dx.doi.org/10.1038/s41416-021-01351-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8144199/
https://www.ncbi.nlm.nih.gov/pubmed/33762723
http://dx.doi.org/10.1038/s41416-021-01351-8

Ejemplares similares